The case for medical treatment in chronic stable coronary artery disease

Archives of Internal Medicine

Volumn 165, Issue 22, 2005, Pages 2587-2589

  Nash, David T ^a,b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE DURATION; HEALTH PROGRAM; HEART EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; LIFE EXPECTANCY; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SHORT SURVEY; SURVIVAL RATE; SURVIVAL TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHRONIC DISEASE; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 28944455061     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.165.22.2587     Document Type: Short Survey

References (19)

1. American Heart Association. Heart Disease and Stroke Statistics-2004 Update. Dallas, Tex: American Heart Association; 2003.
2. Forrester JS, Shah PK. Lipid lowering versus revascularization: an idea whose time (for testing) has come. Circulation. 1997;96:1360-1362.
3. Califf RM, Mark DB. Percutaneous intervention, surgery, and medical therapy: a perspective from the Duke Databank for Cardiovascular Diseases. Semin Thorac Cardiovasc Surg. 1994;6:120-128.
4. Henderson RA, Pocock SJ, Clayton TC, et al; Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2003;42:1161-1170.
5. Greenbaum AB, Califf RM, Jones RH, et al. Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease. Am J Cardiol. 2000;86:1322-1326.
6. Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA. 2003;289:1117-1123.
7. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: Atorvastatin Versus Revascularization Treatment Investigators. N Engl J Med. 1999;341:70-76.
8. Nissen SE, Tuzcu EM, Schoenhagen P, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.
9. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
10. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
11. Blumenthal RS, Cohn G, Schulman SP. Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature. J Am Coll Cardiol. 2000;36:668-673.
12. Hambrecht R, Walther C, Möbius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004;109:1371-1378.
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.
14. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152-160.
15. Olsson AG, Pears J, McKellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001;88:504-508.
16. Shepherd J, Hunninghake B, Stein E, et al. Safety of rosuvastatin. Am J Cardiol. 2004;94:882-888.
17. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003;92(suppl 4B):23K-29K.
18. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
19. Chaitman BR, Pepine CJ, Parker JO, et al; Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-316.